(NASDAQ: CELU) Celularity's forecast annual revenue growth rate of -42.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 10,049.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,423.59%.
Celularity's revenue in 2025 is $44,590,000.On average, 3 Wall Street analysts forecast CELU's revenue for 2025 to be $680,632,664, with the lowest CELU revenue forecast at $653,941,187, and the highest CELU revenue forecast at $700,651,271.
In 2026, CELU is forecast to generate $1,197,913,488 in revenue, with the lowest revenue forecast at $1,150,936,488 and the highest revenue forecast at $1,233,146,237.